Presidio Medical™ Received IDE Approval for Ultra Low Frequency (ULF™) Neuromodulation Clinical Study and Appoints Dimas Jiménez as Chief Financial Officer
On June 12, 2025, San Mateo, California–Presidio Medical, Inc., a global clinical-stage medical device company, received Investigational New Drug (IDE) approval from the U.S. FDA to initiate its global, pivotal randomized controlled trial, the FULFILL Study, in both the United States and Australia. The study will evaluate the company’s proprietary Ultra Low Frequency (ULF™) neuromodulation platform, which delivers therapy through leads implanted in the epidural space, commonly referred to as Spinal Cord St...
